Clinical trial
A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL）
NCT04612582 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL）
- Lead sponsor
- Guangdong Provincial People's Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- January 1, 2020
- Completion date
- June 30, 2023
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.